Similarly, the azacitidine–venetoclax combination achieved a higher CR/CRi rate than induction chemotherapy (56–89% versus 61%) in newly diagnosed IDH-mutated AML, particularly IDH2-mutated AML [93,94]. The gene discussed is IDH2; the disease is acute myeloid leukemia.